These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1544011)

  • 1. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects.
    Eagger S; Morant N; Levy R; Sahakian B
    Br J Psychiatry; 1992 Jan; 160():36-40. PubMed ID: 1544011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
    Kaufer DI; Cummings JL; Christine D
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
    Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
    JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
    Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
    BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
    Gracon SI
    Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
    Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
    JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tacrine: progress in treatment of Alzheimer's disease?].
    Kurz A; Marquard R; Mösch D
    Z Gerontol Geriatr; 1995; 28(3):163-8. PubMed ID: 7664190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrine in Alzheimer's disease.
    Eagger SA; Levy R; Sahakian BJ
    Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
    Foster NL; Petersen RC; Gracon SI; Lewis K
    Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease: how to give and monitor tacrine therapy.
    Woo JK; Lantz MS
    Geriatrics; 1995 May; 50(5):50-3. PubMed ID: 7737527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
    Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
    JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with tacrine (THA) in Alzheimer's disease--evaluation of neuropsychological data.
    Amberla K; Nordberg A; Viitanen M; Winblad B
    Acta Neurol Scand Suppl; 1993; 149():55-7. PubMed ID: 8128841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.
    Wallin AK; Gustafson L; Sjögren M; Wattmo C; Minthon L
    Dement Geriatr Cogn Disord; 2004; 18(2):197-206. PubMed ID: 15211076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.
    Sahakian BJ; Owen AM; Morant NJ; Eagger SA; Boddington S; Crayton L; Crockford HA; Crooks M; Hill K; Levy R
    Psychopharmacology (Berl); 1993; 110(4):395-401. PubMed ID: 7870908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.